Oncotarget

Research Perspectives:

Cyclotherapy: opening a therapeutic window in cancer treatment

Ingeborg M.M. van Leeuwen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:596-600. https://doi.org/10.18632/oncotarget.524

Metrics: PDF 2026 views  |   HTML 2639 views  |   ?  


Abstract

Ingeborg M.M. van Leeuwen1

1 Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Correspondence:

Ingeborg M.M. van Leeuwen, email:

Keywords: Cyclotherapy, chemotherapy, p53, nutlin-3, tenovin-6, leptomycin B, actinomycin D

Received: May 18, 2012, Accepted: June 15, 2012, Published: June 16, 2012

Abstract

Cyclotherapy is a promising endeavor to improve cancer treatment by tackling the dose-limiting side effects of chemotherapy, especially for cancers harboring mutations in the TP53 tumor suppressor. In this particular context, pre-treatment with a p53 activator halts proliferation in healthy tissue, while leaving the p53-deficient tumor susceptible to conventional chemotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 524